This summary is for informational purposes only.

PROTOCOL ID: APD334-202

PROTOCOL TITLE: A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction Therapy in Subjects with Moderately to Severely Active Crohn's Disease

EUDRACT NUMBER: 2019-002895-14

STUDY CENTERS: Multi-center

STUDY START DATE: N/A

FINAL COMPLETION DATE: N/A

Trial was withdrawn by the Sponsor before enrollment due to study re-design.
Trial was re-registered under EudraCT #2020-004775-40.

PHASE OF DEVELOPMENT: Phase 2b

STUDY OBJECTIVES:

Efficacy: To evaluate the dose-response relationship of 2 doses of etrasimod versus placebo as induction therapy in subjects with moderately to severely active Crohn's disease (CD). To select an oral etrasimod dose, based on efficacy and safety, for continued development.

Safety: To evaluate the long-term safety, tolerability, and efficacy of etrasimod in subjects with moderately to severely active Crohn's disease (CD).

NUMBER OF SUBJECTS (PLANNED AND ANALYZED):

No subjects were enrolled.

RESULTS:

Subject Disposition and Demography: Not available

Efficacy results: No efficacy analyses were conducted.

Safety results: As no patients were enrolled, there were no reported adverse events in this study.

CONCLUSION:

No efficacy or safety conclusions were made for this study.